Christopher David Ozeroff net worth and biography

Christopher Ozeroff Biography and Net Worth

VP of ARCA biopharma

Mr. Ozeroff has been ARCA’s Senior Vice President and General Counsel since September 2004. From August 1999, Mr. Ozeroff was previously a partner with the law firm of Hogan & Hartson L.L.P., where he practiced in such areas as finance, acquisitions, public offerings and licensing. Mr. Ozeroff completed his undergraduate degree at Stanford University, and his law degree at the University of Chicago Law School.

What is Christopher David Ozeroff's net worth?: The estimated net worth of Christopher David Ozeroff is at least $0.00 as of April 5th, 2016. Mr. Ozeroff owns 136 shares of ARCA biopharma stock worth more than $0 as of November 13th. This net worth approximation does not reflect any other investments that Mr. Ozeroff may own. Learn More about Christopher David Ozeroff's net worth.
How do I contact Christopher David Ozeroff?: The corporate mailing address for Mr. Ozeroff and other ARCA biopharma executives is 11080 CIRCLEPOINT ROAD SUITE 140, WESTMINSTER CO, 80020. ARCA biopharma can also be reached via phone at (720) 940-2100 and via email at [email protected]. Learn More on Christopher David Ozeroff's contact information.
Has Christopher David Ozeroff been buying or selling shares of ARCA biopharma?: Christopher David Ozeroff has not been actively trading shares of ARCA biopharma during the last ninety days. Most recently, on Monday, November 22nd, Christopher David Ozeroff bought 347 shares of ARCA biopharma stock. The stock was acquired at an average cost of $325.44 per share, with a total value of $112,927.68. Learn More on Christopher David Ozeroff's trading history.
Who are ARCA biopharma's active insiders?: ARCA biopharma's insider roster includes Robert Conway (Chairman), and Christopher Ozeroff (VP). Learn More on ARCA biopharma's active insiders.
Are insiders buying or selling shares of ARCA biopharma?: During the last year, ARCA biopharma insiders bought shares 6 times. They purchased a total of 3,421 shares worth more than $1,666,176.48. The most recent insider tranaction occured on August, 16th when Major Shareholder Henderson Group Plc Janus bought 40 shares worth more than $16,876.80. Insiders at ARCA biopharma own 30.9% of the company. Learn More about insider trades at ARCA biopharma.
Information on this page was last updated on 8/16/2024.

Christopher David Ozeroff Insider Trading History at ARCA biopharma

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/22/2021	Buy	347	$325.44	$112,927.68
4/4/2017	Sell	2	$347.04	$694.08
9/20/2016	Sell	8	$416.16	$3,329.28
4/5/2016	Sell	2	$506.88	$1,013.76	136
3/1/2016	Sell	3	$505.44	$1,516.32	138
9/18/2015	Sell	7	$910.08	$6,370.56	141

Christopher David Ozeroff Buying and Selling Activity at ARCA biopharma

ARCA biopharma Company Overview

ARCA biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with heart failure. It is developing Recombinant Nematode Anticoagulant Protein c2, a protein therapeutic that is in Phase IIb clinical trial for the treatment for COVID-19. The company has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.

Today's Range

Now: N/A

50 Day Range

MA: $384.99

$2.40

$599.04

2 Week Range

Now: N/A

Volume

290,800 shs

Average Volume

607,995 shs

Market Capitalization

$34.82 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.91

Watch this before it gets removed

From Porter & Company | Ad

If you missed it, my emergency election broadcast is now available - but will be removed soon

Click here to watch it now.